PanGenomic Health Inc - Vancouver, Canada-based precision health company - Says subsidiary MUJN Diagnostics Inc has launched its brain-derived neurotrophic factor or BDNF mental health biomarker assessment service. MUJN has also completed its first sale of the point-of-care test to health clinics in Canada. BDNF levels contribute to the survival, development and creation of neurons in the brain.

MUJN Chief Executive Officer Vincent Lum says: "Our strategy is to continue to expand MUJN Diagnostic’s health services beyond our initial Vitamin D assessments to include rapid in-clinic access to a panel of mental health patient point-of-care biomarker assessments...Changes in BDNF levels provide important information for health practitioners when considering treatment options for patients with brain health concerns such as major depressive disorder."

Current stock price: CAD0.035

12-month change: down 83%

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.